2024
CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor.
Hirano H, Naito Y, Sundar R, Komatsu Y, Kurokawa Y, Li J, Ozaka M, Iwatsuki M, Chen J, Yen C, Zalcberg J, Roy A, Chen L, Nishida T, Doi T. CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor. Journal Of Clinical Oncology 2024, 42: tps97-tps97. DOI: 10.1200/jco.2024.42.23_suppl.tps97.Peer-Reviewed Original ResearchDose-escalation partGastrointestinal stromal tumorsProgression-free survivalDays on/2 daysResistance to IMStromal tumorsImatinib-refractory gastrointestinal stromal tumorsInvestigator-assessed progression-free survivalAdvanced gastrointestinal stromal tumorsKinase-domain mutationsOvercome IM resistanceWeeks on/2 weeksDisease control rateDose-limiting toxicitySecond-line settingDuration of responseMaximum tolerated dosePhase I studyPhase 3 studyPhase 1 studySoft tissue sarcomasHsp90 inhibitorsInhibited tumor growthAnti-tumor activityOverall survivalAdjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
Sutton T, Billingsley K, Johnson A, Corless C, Blanke C, Heinrich M, Mayo S. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? Journal Of Surgical Oncology 2024, 130: 40-46. PMID: 38924626, DOI: 10.1002/jso.27654.Peer-Reviewed Original ResearchHigh-risk gastrointestinal stromal tumorsRecurrence-free survivalGastrointestinal stromal tumorsResected gastrointestinal stromal tumorsAdjuvant imatinibOverall survivalStromal tumorsAdjuvant therapyDuration of adjuvant imatinibBenefit of adjuvant therapyMonths of postsurgical follow-upMultivariate Cox proportional hazards modelPostsurgical follow-upKaplan-Meier analysisCox proportional hazards modelsProportional hazards modelRadiographic recurrenceImatinib resistanceReviewed patientsFollow-upImatinibOncological treatmentCytocidal effectCancer CenterPatients
2023
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
Kummar S, Shen L, Hong D, McDermott R, Keedy V, Casanova M, Demetri G, Dowlati A, Melcón S, Lassen U, Leyvraz S, Liu T, Moreno V, Patel J, Patil T, Mallick A, Sousa N, Tahara M, Ziegler D, Norenberg R, Arvis P, Brega N, Drilon A, Tan D. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer 2023, 129: 3772-3782. PMID: 37769113, PMCID: PMC11265530, DOI: 10.1002/cncr.35036.Peer-Reviewed Original ResearchConceptsTropomyosin receptor kinaseNTRK gene fusionsAdult patientsFusion sarcomaAdverse eventsData cutoffGrade 3 treatment-emergent adverse eventsTropomyosin receptor kinase fusion cancerCohort of adult patientsClinical management of adult patientsExtended survival benefitSafety of larotrectinibManagement of adult patientsGastrointestinal stromal tumorsSoft tissue sarcomasTreatment of patientsFirst-in-classGene fusionsInvestigator-assessedNTRK genesReceptor kinaseStromal tumorsSurvival benefitPediatric patientsSolid tumorsRare tumors: Opportunities and challenges from the Children’s Oncology Group perspective
Schultz K, Chintagumpala M, Piao J, Chen K, Shah R, Gartrell R, Christison-Lagay E, Pashnakar F, Berry J, O'Neill A, Vasta L, Flynn A, Mitchell S, Seynnaeve B, Rosenblum J, Potter S, Kamihara J, Rodriguez-Galindo C, Hawkins D, Laetsch T. Rare tumors: Opportunities and challenges from the Children’s Oncology Group perspective. 2023, 2: 100024. PMID: 37829670, PMCID: PMC10566015, DOI: 10.1016/j.ejcped.2023.100024.Peer-Reviewed Original ResearchTumor CommitteeStromal tumorsDesmoplastic small round cell tumorSmall round cell tumorGastrointestinal stromal tumorsNonmelanoma skin cancerRound cell tumorGonadal stromal tumorPleuropulmonary blastomaRare tumorAdrenocortical carcinomaNeuroendocrine tumorsCell tumorsRare cancersChildhood cancerColorectal carcinomaPancreatic tumorsNasopharyngeal carcinomaThyroid carcinomaHigh-quality researchCarcinomaSkin cancerTumorsYoung adultsCancer
2022
Ki‐67 index assessment on FNA specimens of gastrointestinal stromal tumor: Correlation with mitotic rate and potential predictive value for risk stratification
Wang X, Abi‐Raad R, Tang H, Cai G. Ki‐67 index assessment on FNA specimens of gastrointestinal stromal tumor: Correlation with mitotic rate and potential predictive value for risk stratification. Cancer Cytopathology 2022, 130: 974-982. PMID: 35876606, DOI: 10.1002/cncy.22630.Peer-Reviewed Original ResearchConceptsGastrointestinal stromal tumorsKi-67 indexHigh mitotic rateLow mitotic rateCell block sectionsMitotic rateMitotic countRisk stratificationStromal tumorsSurgical specimensRisk of GISTCytology specimensMean Ki-67 indexPotential predictive valueBlock sectionsFine-needle aspiration specimensKi-67 immunostainLMR groupSurgical resectionDistal esophagusTumor sizeSpindle cellsGIST casesFNA specimensPredictive valueHepatic Metastases in Gastrointestinal Stromal Tumors: Oncologic Outcomes with Curative-Intent Hepatectomy, Resection of Treatment-Resistant Disease, and Tyrosine Kinase Inhibitor Therapy Alone
Sutton T, Walker B, Billingsley K, Sheppard B, Corless C, Heinrich M, Mayo S. Hepatic Metastases in Gastrointestinal Stromal Tumors: Oncologic Outcomes with Curative-Intent Hepatectomy, Resection of Treatment-Resistant Disease, and Tyrosine Kinase Inhibitor Therapy Alone. Hepato Pancreato Biliary 2022, 24: s90-s91. DOI: 10.1016/j.hpb.2022.05.170.Peer-Reviewed Original Research
2021
ASO Visual Abstract: The Disease-Free Interval is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor
Sutton T, Walker B, Billingsley K, Sheppard B, Corless C, Heinrich M, Mayo S. ASO Visual Abstract: The Disease-Free Interval is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor. Annals Of Surgical Oncology 2021, 28: 426-427. DOI: 10.1245/s10434-021-10107-w.Peer-Reviewed Original ResearchRecurrent gastrointestinal stromal tumorsDisease-free intervalGastrointestinal stromal tumorsOncologic outcomesStromal tumorsPatientsTumors
2020
A smooth muscle‐derived, Braf‐driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell‐of‐origin
Kondo J, Huh WJ, Franklin JL, Heinrich MC, Rubin BP, Coffey RJ. A smooth muscle‐derived, Braf‐driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell‐of‐origin. The Journal Of Pathology 2020, 252: 441-450. PMID: 32944951, PMCID: PMC7802691, DOI: 10.1002/path.5552.Peer-Reviewed Original ResearchConceptsGastrointestinal stromal tumorsSmooth muscle cellsICC hyperplasiaMuscle cellsTyrosine kinase inhibitor imatinibFrequent driver eventsCommon mesenchymal tumorsSmooth muscle cell progenitorsDevelopment of GISTsKinase inhibitor imatinibLoss of Trp53ICC-DMPGut motilityStromal tumorsMesenchymal tumorsMouse modelInhibitor imatinibInterstitial cellsMutant BRAFBRAF expressionTumorsBRAFHyperplasiaCell progenitorsDriver eventsCalcifying fibrous tumor of the gastrointestinal tract: A clinicopathologic review and update
Turbiville D, Zhang X. Calcifying fibrous tumor of the gastrointestinal tract: A clinicopathologic review and update. World Journal Of Gastroenterology 2020, 26: 5597-5605. PMID: 33071524, PMCID: PMC7545394, DOI: 10.3748/wjg.v26.i37.5597.Peer-Reviewed Original ResearchConceptsFibrous tumorGastrointestinal tractVascular type Castleman's diseaseRare mesenchymal lesionsType Castleman's diseaseInflammatory myofibroblastic tumorAngiomatoid nodular transformationGastrointestinal stromal tumorsSpindle cell proliferationSolitary fibrous tumorBenign mesenchymal neoplasmNodular fibrous pseudotumorLymphoplasmacytic inflammationLocal resectionMyofibroblastic tumorPlexiform fibromyxomaClinicopathologic reviewNodular transformationStromal tumorsCastleman's diseaseMesenchymal lesionsMesenchymal neoplasmsDifferential diagnosisLower riskLarge intestineSolitary Fibrous Tumor of Pancreas With Unusual Features: A Case Report
Afzal A, Maldonado-Vital M, Khan S, Farooque U, Luo W. Solitary Fibrous Tumor of Pancreas With Unusual Features: A Case Report. Cureus 2020, 12: e10833. PMID: 33173639, PMCID: PMC7647364, DOI: 10.7759/cureus.10833.Peer-Reviewed Original ResearchPancreatic solitary fibrous tumorSolitary fibrous tumorGastrointestinal stromal tumorsFibrous tumorDiagnosis of SFTCommon neuroendocrine tumorMalignant clinical courseCluster of differentiationPotential diagnostic pitfallMajority of SFTsClinical courseBiopsied specimensStromal tumorsImmunohistochemical featuresVascular tumorsCase reportNeuroendocrine tumorsDiagnostic challengeDedifferentiated liposarcomaPathological spectrumAnatomic sitesDiagnostic pitfallsFocal positivityHypercellular areasAtypical features
2019
Gastrointestinal Tract
Abi-Raad R, Cai G. Gastrointestinal Tract. 2019, 365-384. DOI: 10.1007/978-3-030-21799-0_13.ChaptersGastrointestinal tract lesionsTract lesionsUltrasound-guided fine-needle aspiration cytologyEndoscopic ultrasound-guided fine-needle aspiration cytologyFine needle aspiration cytologyGastrointestinal stromal tumorsKey cytologic featuresNeedle aspiration cytologySubmucosal lesionsStromal tumorsBarrett's esophagusAppropriate triageGastric adenocarcinomaAncillary studiesDifferential diagnosisAspiration cytologyCytologic featuresEUS-FNAGastrointestinal tractAspiration materialIntestinal tractPreliminary diagnosisLesionsDiagnosisImmediate evaluationSclerosing epithelioid mesenchymal neoplasm of the pancreas – a proposed new entity
Basturk O, Weigelt B, Adsay V, Benhamida J, Askan G, Wang L, Arcila M, Zamboni G, Fukushima N, Gularte-Mérida R, Da Cruz Paula A, Selenica P, Kumar R, Pareja F, Maher C, Scholes J, Oda Y, Santini D, Doyle L, Petersen I, Flucke U, Koelsche C, Reynolds S, Yavas A, von Deimling A, Reis-Filho J, Klimstra D. Sclerosing epithelioid mesenchymal neoplasm of the pancreas – a proposed new entity. Modern Pathology 2019, 33: 456-467. PMID: 31383964, PMCID: PMC7000300, DOI: 10.1038/s41379-019-0334-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorEpithelioid CellsEuropeFemaleGenetic Predisposition to DiseaseHumansImmunohistochemistryJapanMaleMiddle AgedMolecular Diagnostic TechniquesPancreatic NeoplasmsPhenotypeRetrospective StudiesSclerosisStromal CellsTerminology as TopicTreatment OutcomeUnited StatesConceptsEpithelioid mesenchymal neoplasmWhole-exome sequencingMesenchymal neoplasmsMonths of median follow-upNo lymph node metastasisRound-oval nucleiIndolent clinical courseMedian Follow-UpGastrointestinal stromal tumorsFree of diseaseSolid pseudopapillary neoplasmLymph node metastasisUnique histologic featuresPathogenic gene fusionsSpindle cell fasciclesTumor suppressor geneMethylation profilesSingle sample gene set enrichment analysisLack of abnormalitiesNeoadjuvant/adjuvant therapyStromal tumorsClinical coursePancreatic tumorsPseudopapillary neoplasmNode metastasisFirst-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors
Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja E, Nishio M. First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors. Molecular Cancer Therapeutics 2019, 18: molcanther.0831.2018. PMID: 30679388, DOI: 10.1158/1535-7163.mct-18-0831.Peer-Reviewed Original ResearchConceptsGastrointestinal stromal tumorsPreliminary antitumor efficacyDose-escalation phaseAdvanced solid tumorsSolid tumorsTAS-116Eye disordersEscalation phaseFirst-in-human phase I studyPretreated gastrointestinal stromal tumoursHsp90 inhibitorsTreatment-related adverse eventsNon-small cell lung cancerFirst-in-human studyOral Hsp90 inhibitorPhase I studyCell lung cancerPartial responseStromal tumorsDose proportionalityAntitumor efficacySafety profileSystemic exposureAdverse eventsLung cancer
2018
Calcifying Nested Stromal-Epithelial Tumor of the Liver: An Update and Literature Review
Benedict M, Zhang X. Calcifying Nested Stromal-Epithelial Tumor of the Liver: An Update and Literature Review. Archives Of Pathology & Laboratory Medicine 2018, 143: 264-268. PMID: 30354275, DOI: 10.5858/arpa.2017-0346-rs.Peer-Reviewed Original ResearchConceptsStromal-epithelial tumorStromal tumorsCell tumorsMetastatic gastrointestinal stromal tumorsDesmoplastic small round cell tumorSmall round cell tumorRole of chemotherapyGastrointestinal stromal tumorsCases of metastasisSpindle cell tumorsRound cell tumorMyofibroblastic stromaSurgical interventionSynovial sarcomaTumoral recurrenceVascular invasionRare entityHeterotopic ossificationEpithelial tumorsPsammomatous calcificationEpithelioid cellsTumorsLiverOrganoid arrangementVariety of namesComparing the long‐term outcomes among patients with stomach and small intestine gastrointestinal stromal tumors: An analysis of the National Cancer Database
Giuliano K, Ejaz A, Reames BN, Choi W, Sham J, Gage M, Johnston FM, Ahuja N. Comparing the long‐term outcomes among patients with stomach and small intestine gastrointestinal stromal tumors: An analysis of the National Cancer Database. Journal Of Surgical Oncology 2018, 118: 486-492. PMID: 30129672, DOI: 10.1002/jso.25172.Peer-Reviewed Original ResearchConceptsSmall intestine gastrointestinal stromal tumorGastrointestinal stromal tumorsNational Cancer DatabaseOverall survivalStromal tumorsTumor locationCancer DatabaseLarger median tumor sizeStomach gastrointestinal stromal tumorUnadjusted median overall survivalCox proportional hazards modelNational Oncology DatabaseMedian overall survivalMedian tumor sizeWorse prognostic featuresKaplan-Meier methodLong-term prognosisTumor-related factorsLong-term outcomesCases of stomachProportional hazards modelCommon sarcomaTotal patientsPrognostic featuresOncology databaseDistinctive features of gastrointestinal stromal tumors arising from the colon and rectum
Zhu R, Liu F, Grisotti G, Pérez-Irizarry J, Cha CH, Johnson CH, Boffa DJ, Han D, Johung KL, Zhang Y, Khan SA. Distinctive features of gastrointestinal stromal tumors arising from the colon and rectum. Journal Of Gastrointestinal Oncology 2018, 9: 231-240. PMID: 29755761, PMCID: PMC5934147, DOI: 10.21037/jgo.2017.11.12.Peer-Reviewed Original ResearchRectal gastrointestinal stromal tumorGastric gastrointestinal stromal tumorsGastrointestinal stromal tumorsNational Cancer Data BaseAdjuvant therapyOverall survivalSystemic therapyStromal tumorsCases of GISTColonic gastrointestinal stromal tumorsSmall bowel originAdjuvant systemic therapyWorse overall survivalUnique clinicopathologic featuresBowel originTherapy prolongsClinical characteristicsPatient demographicsLocal excisionPrognostic factorsPropensity matchingSurgical treatmentTreatment guidelinesClinicopathologic featuresClinical care
2016
Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?
Giuliano K, Nagarajan N, Canner J, Najafian A, Wolfgang C, Schneider E, Meyer C, Lennon AM, Johnston FM, Ahuja N. Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ? Journal Of Surgical Oncology 2016, 115: 351-357. PMID: 27885685, DOI: 10.1002/jso.24514.Peer-Reviewed Original ResearchConceptsSmall intestine gastrointestinal stromal tumorGastrointestinal stromal tumorsCause-specific mortalityGIST patientsDiagnosis of GISTCases of GISTLarge nation-wide studyGastric gastrointestinal stromal tumorsGastric GIST patientsCommon mesenchymal tumorsFive-year survivalApproval of imatinibNation-wide studySEER databaseStromal tumorsMesenchymal tumorsGastrointestinal tractAge 50PatientsSurvival analysisSimilar outcomesTumorsPrevious reportsFrequent useOutcomesAcute Pancreatitis and Gastroduodenal Intussusception Induced by an Underlying Gastric Gastrointestinal Stromal Tumor: A Case Report
Yildiz M, Doğan A, Koparan I, Adin M. Acute Pancreatitis and Gastroduodenal Intussusception Induced by an Underlying Gastric Gastrointestinal Stromal Tumor: A Case Report. Journal Of Gastric Cancer 2016, 16: 54-57. PMID: 27104028, PMCID: PMC4834622, DOI: 10.5230/jgc.2016.16.1.54.Peer-Reviewed Case Reports and Technical NotesGastrointestinal stromal tumorsGastric gastrointestinal stromal tumorsAcute pancreatitisStromal tumorsGastroduodenal intussusceptionSevere acute pancreatitisGastrointestinal tract tumorsTract tumorsRare tumorCase reportGastrointestinal systemTumorsIntussusceptionPancreatitisUnique findingReportStomach
2015
Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancers
Hellmann MD, Sturm I, Trnkova ZJ, Lettieri J, Diefenbach K, Rizvi NA, Gettinger SN. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancers. Clinical Lung Cancer 2015, 16: 514-522. PMID: 26003007, PMCID: PMC4750397, DOI: 10.1016/j.cllc.2015.04.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungCisplatinContraindicationsDrug InteractionsFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingNeovascularization, PathologicPemetrexedPhenylurea CompoundsPyridinesSurvival AnalysisTreatment OutcomeConceptsEfficacy of regorafenibMedian progression-free survivalChemotherapy-naive patientsProgression-free survivalPhase I trialCell lung cancerLung cancerAcceptable tolerabilityPartial responsePotent antiangiogenic activityI trialStandard dosesPK interactionsAdvanced nonsquamous non-small cell lung cancerNonsquamous non-small cell lung cancerTreatment-related grade 3 adverse eventsNon-small cell lung cancerGrade 3 adverse eventsKinase inhibitorsAntiangiogenic activityMinor pharmacokinetic interactionCombination of bevacizumabAdvanced colorectal cancerGastrointestinal stromal tumorsAdverse events
2014
The Strength and Cooperativity of KIT Ectodomain Contacts Determine Normal Ligand-Dependent Stimulation or Oncogenic Activation in Cancer
Reshetnyak AV, Opatowsky Y, Boggon TJ, Folta-Stogniew E, Tome F, Lax I, Schlessinger J. The Strength and Cooperativity of KIT Ectodomain Contacts Determine Normal Ligand-Dependent Stimulation or Oncogenic Activation in Cancer. Molecular Cell 2014, 57: 191-201. PMID: 25544564, PMCID: PMC4764128, DOI: 10.1016/j.molcel.2014.11.021.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBaculoviridaeBinding SitesCrystallography, X-RayEnzyme ActivationHumansLigandsMiceModels, MolecularMutationNeoplasmsNIH 3T3 CellsProtein BindingProtein FoldingProtein Interaction Domains and MotifsProtein MultimerizationProtein Structure, SecondaryProto-Oncogene Proteins c-kitRecombinant ProteinsSf9 CellsSpodopteraConceptsOncogenic KIT mutationsKIT mutationsGastrointestinal stromal tumorsAcute myeloid leukemiaKIT tyrosine kinase activitySomatic oncogenic mutationsInterstitial pacemaker cellsLigand-dependent stimulationReceptor tyrosine kinase KITStromal tumorsTyrosine kinase KITMyeloid leukemiaReceptor activationPacemaker cellsTyrosine kinase activityCancerKinase KITOncogenic mutationsHematopoietic cellsGerm cellsOncogenic activationActivationCellsReceptor moleculesMutations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply